The Journey of Tirzepatide

Tirzepatide is a 39-amino acid synthetic peptide that is not
absorbed orally due to enzymatic degradation in the GI tract. It is administered by subcutaneous
injection once weekly. Subcutaneous bioavailability is approximately 80%. Peak plasma concentrations
are achieved within 8-72 hours (median ~8-24 hours) after subcutaneous injection, reflecting slow
absorption from the injection site depot. The drug is formulated as an aqueous solution (pH 7.0)
in 2.5, 5, 7.5, 10, 12.5, and 15 mg single-dose pens, enabling dose escalation at 4-week intervals
(starting at 2.5 mg/week). Tirzepatide is a dual GIP/GLP-1 receptor agonist built on a C20 fatty
diacid linker attached to a modified GIP peptide backbone — analogous to semaglutide's albumin-
binding fatty acid strategy but applied to a GIP scaffold with GLP-1 agonist activity engineered
in. The fatty acid linker enables non-covalent albumin binding, reducing renal filtration and
extending the half-life to approximately 5 days.

Tirzepatide has a volume of distribution of approximately 10.3 L
at steady state, slightly smaller than semaglutide (12.5 L) but similarly reflecting near-plasma
confinement due to extensive albumin binding (>99%). The C20 fatty diacid linker provides strong
non-covalent albumin binding analogous to semaglutide's C18 fatty diacid chain, minimizing renal
filtration and slowing receptor internalization. Albumin-bound tirzepatide circulates for extended
periods and crosses into interstitial fluid via transcapillary exchange. CNS access is limited
but sufficient to activate hypothalamic GLP-1R — activating arcuate nucleus and nucleus of the
solitary tract circuits to reduce food intake and enhance satiety. GIPR expression in the CNS
(hypothalamus, reward circuits) contributes to the unprecedented weight loss beyond that achieved
by GLP-1R agonism alone. The drug distributes to the pancreas, gut, and other incretin-responsive
organs via receptor-mediated targeting.

Tirzepatide activates both the GIP receptor (GIPR, a class B GPCR)
and GLP-1 receptor (GLP-1R) simultaneously. At GIPR, tirzepatide behaves as a balanced agonist
(equivalent GIP-like potency). At GLP-1R, tirzepatide is a partial agonist with approximately
5-fold lower intrinsic activity than native GLP-1 but achieves full pharmacological effect at
therapeutic concentrations. Both receptors couple to Gs, activating adenylyl cyclase, raising
cAMP, and activating PKA and EPAC2 to potentiate glucose-stimulated insulin secretion from pancreatic
beta cells. GIP agonism also stimulates glucagon from alpha cells (in contrast to GLP-1's glucagon
suppression) in a glucose-dependent manner — potentially protecting against hypoglycemia. GIP and
GLP-1 receptors are expressed in adipose tissue, where dual agonism enhances lipid metabolism and
fat mobilization — the proposed mechanism for tirzepatide's superior adiposity reduction. The
additive or synergistic effects on hypothalamic circuits (arcuate GIPR + GLP-1R) produce greater
appetite suppression and energy expenditure increase than either agonist alone, explaining the
unprecedented body weight reductions of 20-22% in the SURMOUNT-1/3 trials.

Tirzepatide is degraded by ubiquitous proteolytic enzymes, including
neutral endopeptidases (NEP/neprilysin) and dipeptidyl peptidase IV (DPP-4). The modified GIP
backbone of tirzepatide includes an Aib (alpha-aminoisobutyric acid) at position 2 (analogous to
semaglutide's modification at the equivalent position) to confer DPP-4 resistance — the same amino
acid substitution that protects GLP-1 analogues from rapid in vivo cleavage. The fatty acid linker
provides additional protection from renal filtration and degradative enzymes by albumin shielding.
Metabolites include small peptide fragments and amino acids generated by sequential endopeptidase
and exopeptidase cleavage of the backbone. No CYP450 enzymes are involved in tirzepatide metabolism.
Because GLP-1R agonists delay gastric emptying, tirzepatide can reduce peak concentrations and
time to Cmax of co-administered oral drugs — particularly important for drugs requiring rapid onset
(oral contraceptives, narrow therapeutic index drugs) and potentially requiring timing adjustments.

Tirzepatide metabolites (peptide fragments and amino acids) are
excreted in urine and feces in approximately equal proportions. The parent compound is not excreted
intact in urine due to albumin binding preventing glomerular filtration and rapid tubular catabolism
of any filtered fragments. The elimination half-life is approximately 5 days, enabling once-weekly
dosing. Steady-state plasma concentrations are achieved after approximately 4-5 weeks of weekly
dosing (4-5 half-lives). No dose adjustment is required for renal impairment, as tirzepatide
clearance does not depend on renal excretion of intact drug. Severe renal impairment increases
exposure modestly but not to a clinically meaningful degree. Hepatic impairment does not significantly
alter tirzepatide pharmacokinetics. After treatment discontinuation, pharmacodynamic effects
persist for approximately 4-6 weeks (corresponding to 4-5 half-lives) as plasma concentrations
decline.

Tirzepatide (Mounjaro for T2D; Zepbound for obesity) achieved
unprecedented weight loss in clinical trials: 20.9% average body weight reduction at 72 weeks
in SURMOUNT-1 (15 mg), surpassing all prior approved obesity pharmacotherapies and approaching
surgical weight loss in some patient subgroups. In the SURPASS-2 head-to-head trial, tirzepatide
15 mg achieved superior HbA1c reduction (-2.46%) and weight loss (-12.4 kg) versus semaglutide 1 mg.
The cardiovascular outcomes trial SURMOUNT-MMO showed significant cardiovascular risk reduction
in obesity. Adverse effects mirror GLP-1R agonists: nausea, vomiting, diarrhea (dose-dependent,
reduced with gradual escalation), constipation. The theoretical concern about GIPR agonism
stimulating adipogenesis has not been confirmed clinically — net effect is lipolytic. Medullary
thyroid carcinoma risk (rodent carcinogenicity, precautionary) remains a labeled warning.
Tirzepatide defines the current frontier of pharmacological obesity management.